[Anal fissure. Which first line treatment?].
Slim
K
K
Service de chirurgie générale et digestive, Hôtel-Dieu, boulevard Léon-Malfreyt, 63058 Clermont-Ferrand cedex 01, France. kslim@chu-clermontferrand.fr
Siproudhis
L
L
D019274:Botulinum Toxins, Type A / Q000627:therapeutic use; D004106:Dilatation; D004110:Diltiazem / Q000627:therapeutic use; D019317:Evidence-Based Medicine; D005242:Fecal Incontinence / Q000453:epidemiology / Q000209:etiology; D005401:Fissure in Ano / Q000150:complications / Q000188:drug therapy* / Q000601:surgery*; D006801:Humans; D009465:Neuromuscular Agents / Q000627:therapeutic use; D009543:Nifedipine / Q000627:therapeutic use; D005996:Nitroglycerin / Q000627:therapeutic use; D018579:Patient Selection; D012008:Recurrence; D012307:Risk Factors; D016896:Treatment Outcome; D014665:Vasodilator Agents / Q000627:therapeutic use; D014945:Wound Healing
D009465:Neuromuscular Agents; D014665:Vasodilator Agents; D019274:Botulinum Toxins, Type A; D004110:Diltiazem; D005996:Nitroglycerin; D009543:Nifedipine